Expanding Options for Blood Disorder Patients

Exciting research at Michigan Medicine, the Children’s Hospital of Philadelphia, and Penn Medicine illuminates a path to broader gene therapy for blood disorders, particularly sickle cell anemia ().

To cure blood disorders, //patients must undergo high-dose chemotherapy and bone marrow transplantation. This requires a match between the recipient and donor immune system, but ~30% of patients do not have a match. Even when they do the donor immune system can attack the patient, graft versus host disease.

Gene Therapy: A Promising Approach to Alleviate Chronic Pain
In cell and animal studies, scientists have pinpointed the specific region of a protein that regulates sodium ion channels.

‘Groundbreaking study paves the way for expanded gene therapy in treating blood disorders, with a focus on sickle cell anemia. # Gene therapy, #Blood disorders, #Sickle cell anemia ’

Tweet it Now

Gene therapy corrects the mutation in a patient’s cells but still requires chemotherapy and transplantation of one’s own corrected cells. The new research shows that blood stem cells can be genetically engineered while still in the bone marrow, in a single treatment.

Co-first author Michael Triebwasser, M.D., Ph.D., clinical instructor in Pediatric Hematology and Oncology reported, “This is the first time the blood stem cells that create the blood and immune system over our lifetime can be genetically engineered while still in the bone marrow.

Gene Therapy's Promising Steps in Blood Disorder Research

“This technology can be used to correct disease cause mutations such as the single mutation that causes sickle cell anemia in ~7.5 million people worldwide, and it can be used to control stem cells using messenger RNA (mRNA). To do this we utilized a type of nanoparticle similar to the Pfizer COVID mRNA vaccine but designed it to find these stem cells specifically.”

The risks patients undergo for gene therapy highlight the need for improved treatments. In addition, eliminating the need for stem cell collection and treatment outside the body can cut costs for patients and improve access to critical gene therapies for many patients.

FDA Approves Gene Therapy for Deadly Form of Muscular Dystrophy
The U.S. Food and Drug Administration approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children aged 4 and 5 years of age.

The recently approved gene therapy for another blood disorder, beta-thalassemia, costs $2.8 million dollars.

"This approach is highly flexible and has reduced toxicity when treating stem cells outside the blood compared to current methods. It will hopefully lead to improved methods for correcting stem cells.

Gene Therapy Using Adeno Virus Reverses Age-Related Hearing Loss
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.

“The ultimate goal would be to do these same gene corrections while the stem cells remain in the body. This would open the door for cures in resource-limited countries where the infrastructure for bone marrow transplantation is not present, and the cost is prohibitive.”

Reference:

In vivo hematopoietic stem cell modification by mRNA delivery - (https://www.science.org/doi/10.1126/science.ade6967)

Source-Eurekalert